Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives in the Treatment of Substance Use Disorders—A Scoping Review

Summary & key facts

This review looked at what is known about ibogaine, a plant chemical, as a possible treatment for substance use disorder. The authors found some lab and human studies suggesting ibogaine can reduce withdrawal symptoms and craving and may act on several brain systems at once. But the evidence is mixed and incomplete, there are unresolved safety worries about the heart, and ibogaine products and rules differ a lot between places. The reviewers say more careful research and better quality controls are needed before ibogaine could be used safely in regular medical care.

Key facts:

• About 600,000 people die each year from substance use disorders worldwide, and many of these deaths are linked to opioid use.
• Most approved addiction treatments target only one brain process and often do not stop people from relapsing.
• Ibogaine is an active chemical taken from the Tabernanthe iboga plant that affects several brain pathways, which is why researchers are interested in it for addiction.
• Some preclinical lab studies and some human studies report that ibogaine can reduce withdrawal symptoms and drug craving.
• The published evidence is fragmented and varied in quality, so we do not yet know how reliably ibogaine works for people.
• There are important safety concerns, especially about effects on the heart, and these cardiac risks are not fully resolved.
• Available ibogaine products are not consistently standardized or chemically validated, and many countries lack clear rules for its medical use.
• Researchers have suggested a possible brain 'reset' effect from ibogaine, but this idea is still a hypothesis and needs stronger proof.

Abstract

Substance Use Disorder (SUD) constitutes a major and persistent global public health burden, accounting for approximately 600,000 deaths annually, largely driven by opioid use. Despite substantial advances in addiction neuroscience, currently approved therapeutic strategies remain limited in efficacy, as they predominantly target isolated neurobiological processes and fail to concurrently address core mechanisms such as glutamatergic hyperactivity, mesolimbic hypodopaminergic, and dysfunction of cortical and executive control networks. This mechanistic fragmentation contributes to persistently high relapse rates and underscores the need for integrative and multitarget therapeutic approaches. Within this context, ibogaine has re-emerged as a clinical candidate due to its distinctive multimodal neuropharmacological profile and its reported capacity to modulate multiple pathways implicated in addictive behaviours. However, the clinical translation of ibogaine remains substantially constrained by fragmented and heterogeneous evidence, the absence of regulatory frameworks in several jurisdictions, limited phytochemical validation and standardization of available formulations, and unresolved concerns regarding cardiac safety. This scoping review critically synthesizes the available preclinical and clinical literature on ibogaine in the treatment of SUD, with particular emphasis on reported effects on withdrawal symptoms and craving, dose–response relationships, and the occurrence of cardiac adverse events. By clarifying the current state of the evidence and delineating key translational constraints, this review defines the conditions under which ibogaine, an indole alkaloid isolated from Tabernanthe iboga Baill. (Apocynaceae), may warrant continued investigation. The hypothesis of a neurobiological “reset”, supported by emerging preclinical and clinical data, positions ibogaine as a compound of relevance in addiction research and highlights the need for rigorous pharmacological, toxicological, and regulatory evaluation to inform safer and more standardized clinical pathways.

Topics

Alkaloids: synthesis and pharmacology Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior

Categories

Life Sciences Pharmacology Pharmacology, Toxicology and Pharmaceutics

Tags

Addiction Adverse effect Bioinformatics Clinical trial Indole alkaloid Intensive care medicine Mechanism (biology) Medicine Neuroscience Pharmacology Preclinical research Psychiatry Psychology Substance use Translational research

Substances

Ibogaine

Conditions & symptoms

Addiction Addiction or harmful habbits